Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia Congress

PR65058

BAGSVAERD, Denmark, July 12 /PRNewswire=KYODO JBN/ --

    This material is intended for global medical media only.  

    For journalistic assessment and preparation before publication.  

    Novo Nordisk announced today that data from 28 abstracts will be shared at

the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando,

Florida, from 24-28 July. The WFH Congress is the largest international meeting

for the global bleeding disorders community, taking place every second year.

    The broad spectrum of data demonstrates exciting new advances in the area of

haemophilia and establishes Novo Nordisk's commitment to driving innovation and

research. The comprehensive programme provides updates on Novo Nordisk's

haemophilia pipeline, new clinical data regarding established treatments and

insights into the psychosocial and functional impact of haemophilia on quality

of life.

    Following are key highlights that will be presented at the meeting:

    Monday, July 25, 3:50 pm EDT, Poster Presentation

    - Recombinant factor XIII is safe and effective for prophylaxis in young

children with congenital FXIII A-subunit deficiency: results from an

international phase 3 trial (MP-M-200)

    Tuesday, July 26, 3:30 pm EDT, Poster Presentations

    - Efficacy and safety of turoctocog alfa for prophylaxis and treatment of

bleeding episodes in patients with severe haemophilia A: results from the

guardian(TM)2 trial (P-T-97)

    - First report of safety and efficacy of a glycoPEGylated FVIII (N8-GP) in

previously treated paediatric patients with severe haemophilia A - results from

the international phase 3 pathfinder(TM)5 trial (P-T-103)

    - Psychosocial impact of mild to severe haemophilia B on affected adults

and children: methods and demographics of the bridging haemophilia B

experiences results and opportunities into solutions (B-HERO-S) study (PO-T-26)

    Wednesday, July 27, 3:30 pm EDT, Poster Presentations

    - Bleeding characteristics of patients with congenital haemophilia and

inhibitors: data from a postmarketing study of recombinant activated factor VII

(SMART-7) (P-W-79)

    "The presentation of 28 abstracts at WFH 2016 is unparalleled and a clear

signal to the haemophilia community that Novo Nordisk is committed to finding

solutions to improve the lives of people living with haemophilia worldwide,"

said Mads Krogsgaard Thomsen, executive vice president and chief science

officer of Novo Nordisk. "We look forward to the opportunity for scientific

exchange at this important meeting."

    The abstracts above are a sampling of the data that will be presented or

published by Novo Nordisk. For a complete list of abstracts please visit:

http://www.wfh.org/congress/2016_Abstracts

    About Novo Nordisk  

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in

75 countries and markets its products in more than 180 countries. For more

information, visit novonordisk.com [http://novonordisk.com ], Facebook

[http://www.facebook.com/novonordisk ], Twitter

[http://www.twitter.com/novonordisk ], LinkedIn

[http://www.linkedin.com/company/novo-nordisk ], YouTube

[http://www.Youtube.com/novonordisk ]  

    Further information

    Media:

    Katrine Sperling

    +45-4442-6718

    krsp@novonordisk.com

    Asa Josefsson

    +45-3079-7708

    aajf@novonordisk.com

    Courtney Mallon

    +1-609-786-4079

    cyml@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com

    Melanie Raouzeos

    +45-3075-3479

    mrz@novonordisk.com

    Kasper Veje (US)

    +1-609-235-8567

    kpvj@novonordisk.com

    SOURCE: Novo Nordisk